Relevant bibliographies by topics / Antimuscarinics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Antimuscarinics'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antimuscarinics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antimuscarinics"

1

Hopkinson, VCG, and I. Pearce. "Pharmacotherapy in overactive bladder." Journal of Clinical Urology 11, no. 1 (2017): 38–47. http://dx.doi.org/10.1177/2051415817738471.

Full text
Abstract:
Overactive bladder syndrome (OAB) has a high prevalence within the population and has a negative effect on quality of life. Although the precise pathophysiology has yet to be fully elucidated, pharmacotherapeutic agents have been developed targeting two main pathways, antimuscarinic drugs and β3-adrenoreceptor agonists. Conservative management strategies, for example, bladder training, should be used as first-line treatment, with pharmacotherapy used as an adjunct if this is insufficiently effective. Antimuscarinics have a moderate effect on treating the symptoms of OAB, are associated with si
APA, Harvard, Vancouver, ISO, and other styles
2

Athanasopoulos, Anastasios, and Konstantinos Giannitsas. "An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder." Advances in Urology 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/820816.

Full text
Abstract:
Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical treatment of overactive bladder. They offer significant improvements in symptoms and patients’ quality of life. Antimuscarinics are generally well tolerated with mild and predictable side effects. Available antimuscarinics have small, yet statistically significant, differences in their efficacy and tolerability profiles. In clinical practice, finding the agent that offers the optimum balance of efficacy and side effects for an individual patient remains the major challenge
APA, Harvard, Vancouver, ISO, and other styles
3

Pranoto, Inez, Tiara Schwarze-Taufiq, Katherine Hui, et al. "DISTINCTIVE NEURONAL RESPONSES TO VARIOUS ANTICHOLINERGICS IN THE ACT COHORT HIPSC-DERIVED NEURONS." Innovation in Aging 8, Supplement_1 (2024): 877–78. https://doi.org/10.1093/geroni/igae098.2838.

Full text
Abstract:
Abstract Anticholinergic medications remain widely used among older adults despite evidence of safety concerns, including dementia risk. Clinical cohort studies have linked certain anticholinergic classes, such as antidepressants and bladder antimuscarinics, to higher dementia risk. However, distinguishing whether this association stems from individuals’ predisposed conditions or drug-induced neuronal dysfunctions remains challenging. To address this, we used human induced pluripotent stem cell-derived neurons (hiPSC-Ns) from participants in the Adult Changes in Thought Study (ACT) aging study
APA, Harvard, Vancouver, ISO, and other styles
4

Piecoro, Lance T., Daniel P. Wermeling, Frederick A. Schmitt, and J. Wesson Ashford. "Seizures in Patients Receiving Concomitant Antimuscarinics and Acetylcholinesterase Inhibitor." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, no. 5 (1998): 1129–32. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03944.x.

Full text
Abstract:
Seizures occurred in two patients with probable Alzheimer's disease who were receiving long‐term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. In both patients seizures were associated with discontinuation of short‐term agents with high antimuscarinic properties. Hence, abrupt discontinuation of antimuscarinics or anticholinergics with high antimuscarinic properties in patients receiving long‐term acetylcholinesterase inhibition therapy may be associated with a reduction of seizure threshold. With increasing administration of acetylcholinesterase inhibitors for pa
APA, Harvard, Vancouver, ISO, and other styles
5

Sartori, Luisa Gracio Ferreira, Bruno Monteiro Nunes, Daniela Farah, et al. "Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 45, no. 06 (2023): 337–46. http://dx.doi.org/10.1055/s-0043-1770093.

Full text
Abstract:
Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic
APA, Harvard, Vancouver, ISO, and other styles
6

Liu, Qiang, Deyi Luo, Tongxin Yang, Banghua Liao, Hong Li, and Kun-Jie Wang. "Protective Effects of Antimuscarinics on the Bladder Remodeling After Bladder Outlet Obstruction." Cellular Physiology and Biochemistry 44, no. 3 (2017): 907–19. http://dx.doi.org/10.1159/000485358.

Full text
Abstract:
Background/Aims: Overactive bladder associated with bladder outlet obstruction (BOO) is a highly prevalent condition, which is usually treated with antimuscarinics. However, the potential effects of antimuscarinics on the structure and function of bladder have not been investigated thus far. Methods: Sprague-Dawley(R) rats accepted bladder neck obstruction surgery or sham surgery, and then received treatment of three different antimuscarinics (Solifenacin, Darifenacin, and Tolterodine) or vehicle. After 3, 6 and 12 weeks, the bladder function and structure were measured. The effect of antimusc
APA, Harvard, Vancouver, ISO, and other styles
7

Wagg, Adrian, Demitri Diles, and Todd Berner. "Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data." Journal of Health Economics and Outcomes Research 3, no. 1 (2016): 43–55. http://dx.doi.org/10.36469/9841.

Full text
Abstract:
Background: Overactive bladder (OAB) is a chronic condition which may be associated with a significant negative impact on quality of life. Antimuscarinic drugs are currently the mainstay of medical therapy, but persistence and adherence are generally poor. Treatment switching may be considered in order to maximise benefits from pharmacological therapy, but there are relatively few data on OAB therapy switching to second and third-lines of medication. There are also few formal analyses on the impact of age, gender and choice of initial OAB drug on discontinuation rates. Objectives: To investiga
APA, Harvard, Vancouver, ISO, and other styles
8

Andersson, Karl-Erik. "Drugs and future candidates." Canadian Urological Association Journal 5, no. 5-S2 (2013): 131. http://dx.doi.org/10.5489/cuaj.710.

Full text
Abstract:
Antimuscarinic drugs are still first-line treatment for the symptomsof overactive bladder (OAB) and are associated with good initialresponse rates. Adverse effects and decreasing efficacy overthe longer term do, however, limit their overall effectiveness. Assuch, alternatives to antimuscarinics are needed. The recognitionof the functional contribution of the urothelium, the spontaneousmyocyte activity during bladder filling, and the diversity of nervetransmitters involved in the symptoms of the OAB has sparkedinterest in pharmacologic manipulation of both peripheral andcentral pathophysiology.
APA, Harvard, Vancouver, ISO, and other styles
9

Mandpe, Pankaj, Bala Prabhakar, and Pravin Shende. "Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome." Current Drug Metabolism 21, no. 2 (2020): 79–88. http://dx.doi.org/10.2174/1389200221666200425211139.

Full text
Abstract:
Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved β3-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome. Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical t
APA, Harvard, Vancouver, ISO, and other styles
10

Trivedi, Sameer, Pranab Patnaik, Yashpal Ramole, Faiz Ahmed Khan, Ragini Srivastava, and Udai Shankar Dwivedi. "Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder." Clinical Medicine Insights: Urology 12 (January 2019): 117956111986490. http://dx.doi.org/10.1177/1179561119864907.

Full text
Abstract:
Background: This study compared urinary and serum nerve growth factor levels and serum C-reactive protein levels in patients with overactive bladder, before and after treatment with antimuscarinic agents, to evaluate their diagnostic and therapeutic importance. Methods: This was a prospective case-control study conducted between February 2014 and December 2014 which included patients with a confirmed diagnosis of overactive bladder (overactive bladder group) and healthy controls (control group). All patients visiting urology out-patient department with urgency, frequency, and urge incontinence
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antimuscarinics"

1

Zhang, Yan. "Associations of bladder antimuscarinics with delirium and antipsychotics utilization in nursing homes in Iowa." Diss., University of Iowa, 2018. https://ir.uiowa.edu/etd/6348.

Full text
Abstract:
Bladder antimuscarinic medications (BAMs) are commonly used among the aged population to manage urinary incontinence (UI), which is a frequent health problem among nursing home (NH) residents. However, a number of BAMs produce anticholinergic effects in the central nervous system (CNS), and may thereby cause delirium and lead to antipsychotic medication (APM) use. This study examined the associations of BAMs and delirium incidence, and the associations of BAMs and APM initiations in NHs in Iowa. The main data sources were Medicare data, Minimum Data Set (MDS), and the Online Survey Certificati
APA, Harvard, Vancouver, ISO, and other styles
2

Moga, Daniela Claudia. "Bladder antimuscarinics use in the veterans affairs community living centers: description of medication use and evaluation of risks and benefits." Diss., University of Iowa, 2012. https://ir.uiowa.edu/etd/2586.

Full text
Abstract:
Urinary incontinence, one of the most prevalent conditions in elderly living in nursing homes (NH) was shown to significantly impact patient's quality of life (QOL) and health outcomes. Bladder antimuscarinics (BAM), the main drug class to treat urinary incontinence, have limited effects in managing the condition; however, given their anticholinergic properties and the characteristics of those living in NH, BAM could potentially lead to serious health consequences in this population. We conducted a retrospective cohort study with a ne
APA, Harvard, Vancouver, ISO, and other styles
3

Hudkins, Robert Lee. "New Antimuscarinic Agents for Improved Treatment of Poisoning by Cholinesterase Inhibitors." VCU Scholars Compass, 1988. http://scholarscompass.vcu.edu/etd/5074.

Full text
Abstract:
Poisoning by organophosphate cholinesterase inhibitors results in a rapid rise in acetylcholine (ACh) in the synapse and many pronounced pharmacological effects in numerous tissues in the body. The treatment for organophosphorus poisoning involves administration of a cholinesterase—reactivating oxime to restore the activity of the cholinesterase and an antimuscarinic agent to block the response to the excess ACh. Presently atropine is the standard antimuscarinic agent used clinically as an antidote. This research was directed toward finding an antimuscarinic agent better than atropine as an an
APA, Harvard, Vancouver, ISO, and other styles
4

Löhrer-Camenzind, David Johannes. "What is the antimuscarinic of choice for treatment of overactive bladder? : a network meta-analysis /." [S.l.] : [s.n.], 2009. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000281136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Obied, Taghrid Yousef Rashid. "Prediction of in-vivo antimuscarinic activity (AMA) by in-vitro receptor binding assessment and PK/PD modeling for prototypical drugs /." Available to VCU users online at:, 2007. http://hdl.handle.net/10156/200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Obied, Taghrid Y. "Prediction of In-Vivo Antimuscarinic Activity (AMA) by In-Vitro Receptor Binding Assessment and PK/PD Modeling For Prototypical Drugs." VCU Scholars Compass, 2007. http://scholarscompass.vcu.edu/etd/1348.

Full text
Abstract:
Purpose: To establish a tool, termed as antimuscarinic activity (AMA), to predict the incidence of antimuscarinic adverse events (AMAEs).Methods: A literature review, focused on drugs having off-target interaction with muscarinic receptors, was performed. Prototypical drugs olanzapine, diphenhydramine, paroxetine were selected for the analysis. Scopolamine and darifenacin were included as positive and negative controls, respectively. Physiochemical properties, pharmacokinetic data, and clinical incidence of AMAEs for the selected drugs were collected from reported literature. Extrapolation of
APA, Harvard, Vancouver, ISO, and other styles
7

Chang, Yu-Cheng, and 張幼誠. "Compared Cost-Effectiveness of Solifenacin with Other Antimuscarinics in Patients with Overactive Bladder Symptoms: Systematic Reviews and Meta-Analysis." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/07427713361681601629.

Full text
Abstract:
碩士<br>高雄醫學大學<br>醫務管理暨醫療資訊學系碩士在職專班<br>105<br>Purpose To understand the efficacy of solifenacin compared with other antimuscarinics to treat idiopathic overactive bladder patients. Via the systematic reviews and meta-analysis of the literatures for the cost-effectiveness of antimuscarinics in managing idiopathic overactive bladder patients, the results can provide the physician the best chose to treat idiopathic overactive bladder patients. Method Two Urologists searched the evidence-based databases ( retrospective study), to find the cost-effectiveness study of antimuscarinics in managing idio
APA, Harvard, Vancouver, ISO, and other styles
8

Wu, Wen-Yih, and 吳文毅. "Urodynamic evaluation of antimuscarinic drug effect on lower urinary tract function in women with overactive bladder." Thesis, 2006. http://ndltd.ncl.edu.tw/handle/45965739182391802006.

Full text
Abstract:
碩士<br>國立臺灣大學<br>臨床醫學研究所<br>94<br>Summary Background The International Continence Society (ICS) in 2002 derived a consensus for symptomatic definition of overactive bladder (OAB) as urinary urgency, with or without urge incontinence, usually with urinary frequency (voiding eight or more times in a 24-hour period), and nocturia (awakening two or more times at night to void), in the absence of pathologic or metabolic factors that would explain these symptoms (Abrams, 2002). OAB occurs in an estimated 17% of the population, and the frequency increases with age in the United States (Stewart, 2003)a
APA, Harvard, Vancouver, ISO, and other styles
9

Reichel, Dirk. "Synthese und Eigenschaften neuer Antimuscarinika aus der Stoffklasse der (Aminoalkyl)(hydroxymethyl)diorganylsilane und -germane sowie der (Aminoalkyl)diorganylgermanole /." 1994. http://www.gbv.de/dms/bs/toc/182433188.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gencarelli, Manuela. "Revisiting targets for HCN blockers in the heart and urinary bladder: evidence for antimuscarinic activity in human atrial preparations, rat urinary bladder and recombinant muscarinic receptors." Doctoral thesis, 2022. http://hdl.handle.net/2158/1280560.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antimuscarinics"

1

Laurén, Leena. Radioreceptor assay of benzodiazepine and antimuscarinic drugs. L. Laurén, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Johansson, Gary. Quinuclidine derivatives as antimuscarinic agents: Synthesis and structure-activity relationships. Acta Universitatis Upsaliensis, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Reichel, Dirk. Synthese und Eigenschaften neuer Antimuscarinika aus der Stoffklasse der (Aminoalkyl)(hydroxymethyl)diorganylsilane und -germane sowie der (Aminoalkyl)diorganylgermanole. [s.n.], 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chapple, Christopher R., and Altaf Mangera. Urgency incontinence and overactive bladder. Edited by Christopher R. Chapple. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0040.

Full text
Abstract:
Overactive bladder (OAB) is very prevalent and may be very bothersome. In this chapter, we describe the various definitions associated with this condition, its assessment and management. The definitions for lower urinary tract symptoms have been standardized by the International Continence Society. OAB is a symptomatic diagnosis after all other pathology has been excluded. Important assessments include a frequency volume chart and in some cases urodynamic studies. Here we describe the important parameters which should be sought from a frequency volume chart. In addition, the relationship to th
APA, Harvard, Vancouver, ISO, and other styles
5

Pharmacology of antimuscarinic agents. CRC Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brüggmann, Jörg. Molecular Modeling-Untersuchungen zum Rezeptorbindungsverhalten von antimuscarinisch wirksamen Carbo-/Sila-Analoga verschiedener Aminoalkanole. 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kropfgans, Martin Richard. Synthese und Eigenschaften neuer Antimuscarinika aus den Stoffklassen der (Aminoalkyl)(hydroxymethyl)diorganylsilane, (Aminoalkyl)(mercaptomethyl)diorganylsilane, (Aminoalkyl)diorganylsilanole und (Aminoalkyl)triorganylsilane. 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antimuscarinics"

1

Osman, Nadir I., and Christopher R. Chapple. "Antimuscarinics." In Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118437889.ch9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Prentice, Bernadette, Adam Jaffe, and Paul S. Thomas. "Antimuscarinics." In Compendium of Inflammatory Diseases. Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Robert, Richard C. "Antimuscarinics and Antihistamines." In Anesthesia complications in the dental office. John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781119053231.ch22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Goodridge, Sophia Delpe, and Leslie M. Rickey. "Medical Therapy with Antimuscarinics and ß3-Agonists." In Female Urinary Incontinence. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-84352-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shah, Milap, B. M. Zeeshan Hameed, Amelia Pietropaolo, and Bhaskar K. Somani. "Use of Drugs to Reduce the Morbidity of Ureteral Stents." In Urinary Stents. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04484-7_7.

Full text
Abstract:
AbstractDouble ureteral stents are amongst the commonest procedures performed in urology. However, there are complications such as infection, and encrustation associated with its use, together with uncomfortable lower urinary tract symptoms (LUTS). The latter are known as stent related symptoms (SRS) and are commonly reported in the scientific literature. SRS mentioned in literature are urgency, frequency, dysuria, haematuria, pain in the suprapubic and flank region. These can result in decreased sexual activity, reduced work performance, as well as decreased quality of life (QoL) in more than
APA, Harvard, Vancouver, ISO, and other styles
6

Tattersfield, Anne E., and Martin W. McNicol. "Antimuscarinic Drugs." In Treatment in Clinical Medicine. Springer London, 1987. http://dx.doi.org/10.1007/978-1-4471-3132-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McCombe, Kate, and Lara Wijayasiri. "Antimuscarinic Drugs." In The Primary FRCA Structured Oral Examination Study Guide 2, 3rd ed. CRC Press, 2025. https://doi.org/10.1201/9781003276470-22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, et al. "Antimuscarinic/Anticholinergic Agent." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1361.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smith, Ariana L., and Alan J. Wein. "Antimuscarinic Pharmacotherapy for Overactive Bladder." In Contemporary Pharmacotherapy of Overactive Bladder. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-97265-7_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chapple, Christopher R., Dominic Muston, and Zoe S. Kopp. "Antimuscarinic Treatments in Overactive Bladder." In Evidence-Based Urology. Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444323146.ch19.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antimuscarinics"

1

Celis Preciado, Carlos Andrés, Horacio Giraldo, Dario Londoño, and Ingrid Rodriguez. "Glaucoma risk due to antimuscarinics, not a class effect: A systematic review." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carnini, Chiara, Nicola Cesari, Karin Rudolph та ін. "Bronchoprotective activity and safety evaluation of the novel antimuscarinic/β2 agonist (MABA) CHF6366 in dogs". У ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa1804.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schmid, K., S. Pascual, E. Garcia Gil, S. Ortiz, and JM Jansat. "Pharmacokinetics and Safety of Aclidinium Bromide, a Novel, Long-Acting Antimuscarinic, in Subjects with Renal Impairment." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4554.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Sheena, Stuart Marshall, Susan Summerhill, et al. "The In-Vitro Pharmacology Of PF-4348235 At Recombinant Receptors - A Novel Inhaled Dual Antimuscarinic/Beta2 Adrenoceptor Agonist." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Patel, Sheena, Stuart Marshall, Susan Summerhill, et al. "The In-Vitro Pharmacology Of PF-4348235 At Native Receptors - A Novel Inhaled Dual Antimuscarinic/Beta2 Adrenoceptor Agonist." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1608.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Philip, James, Kathryn Hulland, Nick Clarke, Christelle Perros-Huguet, and Mike Yeadon. "Demonstration Of Single And Dual Pharmacology In Vivo Of PF-4348235: A Novel Inhaled Dual Antimuscarinic/2 Agonist." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1609.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sansbury, L., D. Hinds, J. Chao, S. Semus, and S. Zhang. "Treatment Sequencing Among Asthma Patients Who Were Newly Treated with Long-Acting Antimuscarinic Antagonist (LAMA) in the United States." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1828.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jones, PW, A. Agusti, P. Chanez, et al. "A Phase III Study Evaluating Aclidinium Bromide, a Novel Long-Acting Antimuscarinic, in Patients with COPD: ACCLAIM/COPD I." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a6180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rennard, S., J. Donohue, E. Bateman, N. Gross, E. Garcia Gil, and C. Caracta. "Efficacy and Safety of the Novel, Long-Acting Antimuscarinic, Aclidinium Bromide, in COPD Patients in a Phase III Study: ACCLAIM/COPD II." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a6178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hulland, Kathryn, James Philip, Isabelle Delescluse, Nick Clarke, Christelle Perros-Huguet, and Mike Yeadon. "Duration Of Single And Dual Pharmacology In Vivo Of PF-4348235: A Novel Inhaled Dual Antimuscarinic/ß2 Agonist In Conscious Guinea Pigs." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1610.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antimuscarinics"

1

Yang, Nannan, Qiaoyan Wu, Faren Xu, and Xiaopeng Zhang. Comparisons of therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.7.0095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antimuscarinics' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography